These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 15981008)

  • 1. Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomised double-blind study.
    Mahé I; Bergmann JF; d'Azémar P; Vaissie JJ; Caulin C
    Eur J Clin Pharmacol; 2005 Jul; 61(5-6):347-51. PubMed ID: 15981008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
    Righini M; Galanaud JP; Guenneguez H; Brisot D; Diard A; Faisse P; Barrellier MT; Hamel-Desnos C; Jurus C; Pichot O; Martin M; Mazzolai L; Choquenet C; Accassat S; Robert-Ebadi H; Carrier M; Le Gal G; Mermilllod B; Laroche JP; Bounameaux H; Perrier A; Kahn SR; Quere I
    Lancet Haematol; 2016 Dec; 3(12):e556-e562. PubMed ID: 27836513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Two models of thromboprophylaxis in acutely ill medical inpatients].
    Luba M; Firek A; Kochanowski Z
    Pol Arch Med Wewn; 2007 Apr; 117(4):31-7. PubMed ID: 17722473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of weight-adapted nadroparin calcium vs. heparin sodium in prevention of clinically evident thromboembolic complications in 1,190 general surgical patients.
    Egger B; Schmid SW; Naef M; Wildi S; Büchler MW
    Dig Surg; 2000; 17(6):602-609. PubMed ID: 11155006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of the low-molecular-weight heparin CY 216 in the prevention of fatal pulmonary embolism and thromboembolic death in general surgery. A multicentre, double-blind, randomized, controlled clinical trial versus placebo (STEP). STEP Study Group.
    Pezzuoli G; Neri Serneri GG; Settembrini PG; Coggi G; Olivari N; Negri G; Codemo R; Galli G; Roveri S
    Haemostasis; 1990; 20 Suppl 1():193-204. PubMed ID: 1964662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Rationalization of risk factors for venous thromboembolism in medical inpatients. A prospective study].
    Pottier P; Planchon B; Truchaud F; Pistorius MA; Furic I; Grolleau JY
    J Mal Vasc; 2000 Oct; 25(4):241-9. PubMed ID: 11060418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery.
    Nurmohamed MT; van Riel AM; Henkens CM; Koopman MM; Que GT; d'Azemar P; Büller HR; ten Cate JW; Hoek JA; van der Meer J; van der Heul C; Turpie AG; Haley S; Sicurella A; Gent M
    Thromb Haemost; 1996 Feb; 75(2):233-8. PubMed ID: 8815566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.
    Samama MM; Cohen AT; Darmon JY; Desjardins L; Eldor A; Janbon C; Leizorovicz A; Nguyen H; Olsson CG; Turpie AG; Weisslinger N
    N Engl J Med; 1999 Sep; 341(11):793-800. PubMed ID: 10477777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France.
    Fraisse F; Holzapfel L; Couland JM; Simonneau G; Bedock B; Feissel M; Herbecq P; Pordes R; Poussel JF; Roux L
    Am J Respir Crit Care Med; 2000 Apr; 161(4 Pt 1):1109-14. PubMed ID: 10764298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.
    Davis R; Faulds D
    Drugs Aging; 1997 Apr; 10(4):299-322. PubMed ID: 9108990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial.
    Kalfarentzos F; Stavropoulou F; Yarmenitis S; Kehagias I; Karamesini M; Dimitrakopoulos A; Maniati A
    Obes Surg; 2001 Dec; 11(6):670-6. PubMed ID: 11775562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
    Leizorovicz A; Cohen AT; Turpie AG; Olsson CG; Vaitkus PT; Goldhaber SZ;
    Circulation; 2004 Aug; 110(7):874-9. PubMed ID: 15289368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV; Howes J; Sharma V; Kadziola Z
    Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer.
    Simonneau G; Laporte S; Mismetti P; Derlon A; Samii K; Samama CM; Bergman JF;
    J Thromb Haemost; 2006 Aug; 4(8):1693-700. PubMed ID: 16796710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of low molecular weight heparin on survival in patients with advanced malignancy.
    Klerk CP; Smorenburg SM; Otten HM; Lensing AW; Prins MH; Piovella F; Prandoni P; Bos MM; Richel DJ; van Tienhoven G; Büller HR
    J Clin Oncol; 2005 Apr; 23(10):2130-5. PubMed ID: 15699479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study.
    Agnelli G; Gussoni G; Bianchini C; Verso M; Mandalà M; Cavanna L; Barni S; Labianca R; Buzzi F; Scambia G; Passalacqua R; Ricci S; Gasparini G; Lorusso V; Bonizzoni E; Tonato M;
    Lancet Oncol; 2009 Oct; 10(10):943-9. PubMed ID: 19726226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group.
    Bergmann JF; Neuhart E
    Thromb Haemost; 1996 Oct; 76(4):529-34. PubMed ID: 8902991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nadroparin or fondaparinux versus no thromboprophylaxis in patients immobilised in a below-knee plaster cast (PROTECT): A randomised controlled trial.
    Bruntink MM; Groutars YME; Schipper IB; Breederveld RS; Tuinebreijer WE; Derksen RJ;
    Injury; 2017 Apr; 48(4):936-940. PubMed ID: 28279428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Home therapy with LMWH in deep vein thrombosis: randomized study comparing single and double daily administrations.
    Bellosta R; Ferrari P; Luzzani L; Carugati C; Cossu L; Talarico M; Sarcina A
    Angiology; 2007; 58(3):316-22. PubMed ID: 17626986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Determination of factor Xa inhibition doses of low-molecular heparin, nadroparin and reviparin in urological patients].
    Pavlović S; Zivković S; Koraćević G
    Vojnosanit Pregl; 2007 Aug; 64(8):538-42. PubMed ID: 17874721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.